methotrexate

P3, N=150, Active, not recruiting, George Washington University | Trial completion date: Feb 2030 --> Aug 2027 | Trial primary completion date: Feb 2030 --> Aug 2027

Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI.

Management of cancer during pregnancy should be grounded in a values-based informed-consent process outlining maternal and fetal risks and anticipated benefits. Diagnostic evaluation should follow the as low as reasonably achievable (ALARA) principle, with timing of diagnostic studies individualized based on urgency of cancer detection, potential dangers of delay, and the balance of risks to both the pregnant patient and her embryo or fetus. Due to significant risk of harm to the developing embryo and/or fetus, systemic therapy should be deferred until the second trimester. Methotrexate, hormonal therapies, human epidermal growth factor receptor 2-targeted agents, vascular endothelial growth factor and poly (ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and all cellular therapies are contraindicated during pregnancy, regardless of gestational age. For patients who wish to continue their pregnancy, delivery should be planned at or after 37 weeks, with the final chemotherapy dose scheduled 2-4 weeks before birth. Referral to psychosocial support services is essential to address emotional and practical challenges, reduce distress, and support shared decision making.Additional information is available at www.asco.org/survivorship-guidelines.

The patient underwent five cycles of intravitreal methotrexate for presumed uveal lymphoma involving the ciliary body with pseudo-keratic precipitates before a nasal biopsy confirmed recurrent ENKL...The IL-10/IL-6 ratio is of limited value in the diagnosis of T-cell lymphoma affecting intraocular structures. This case highlights the critical role of UBM in identifying ciliary body involvement of intraocular malignancies.

Functionally, TRAC-TCR-T cells exhibited enhanced interferon (IFN)-γ/tumor necrosis factor alpha (TNF-α) secretion and reduced exhaustion markers versus lentiviral counterparts, while maintaining equivalent tumor clearance efficacy in vitro and in xenograft models. In conclusion, this integrated platform mitigates viral vector risks, alleviates concerns of CRISPR-associated genomic instability, and provides a good manufacturing practice (GMP)-compatible approach that may facilitate the development of safer adoptive TCR-T immunotherapies.

The condition was refractory to initial methotrexate and isotretinoin therapy. We report a rare and clinically challenging case of RDD diagnosed with the aid of histopathology and immunohistochemistry. Additionally, we emphasize the role of a combined approach of serial surgical excisions and systemic dapsone therapy.

The components of Sinningia reitzii, mainly the ESR, are promising sources of drugs that combine analgesic and antitumor effects, without systemic toxicity.

KL130008 demonstrated potential for sustained efficacy and safety in the treatment of RA.

P3, N=150, Active, not recruiting, George Washington University | Enrolling by invitation --> Active, not recruiting

To improve the tolerability of post-transplant maintenance and outcomes despite poor risk disease genetics, we conducted a phase 1 study of venetoclax/FluBu2 RIC transplantation with tacrolimus/methotrexate GVHD prophylaxis followed by all-oral venetoclax/decitabine-cedazuridine (ven/dec-c) maintenance in poor-risk MDS/AML patients (N=30). PROs assessed in first 6-months of maintenance were stable except for emotional function, which improved (P=0.008). Trial is registered at clinicaltrials.gov/NCT03613532.

This study aimed to compare treatment options: one combination of tumor necrosis factor inhibitors (adalimumab, etanercept) with methotrexate (MTX) and second treatment with anti-interleukin-6 (tocilizumab) - to determine whether cardiovascular effects are driven primarily by disease activity reduction or through distinct effects based on the mechanism of action. Biologics, irrespective of their specific mechanisms, significantly reduce disease activity, which positively influences LV mass and reduces the incidence of LV hypertrophy. Additionally, biologics do not adversely affect cardiac electrical function.

Drug sensitivity analysis showed that the risk score was significantly correlated with the sensitivity to various chemotherapeutic drugs (e.g., Methotrexate, Paclitaxel). This study established a reliable prognostic risk scoring model for HCC by screening differentially expressed glycolysis-related miRNAs, which effectively distinguishes between high-risk and low-risk patients and predicts patient survival. Additionally, the model is closely associated with the immune microenvironment and drug sensitivity, offering strong support for personalized treatment and clinical decision-making in HCC.